Home
/
Matinas BioPharma Holdings, Inc.
/
Financials
/
Quarterly
Matinas BioPharma Holdings, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Matinas BioPharma Holdings, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2019
Jun 30, 2019
$89.8K
Aug 13, 2019
Q3
2018
Sep 30, 2018
$119.8K
Nov 9, 2018
Q2
2019
Jun 30, 2018
$89.8K
Aug 13, 2019
Q1
2019
Mar 31, 2018
$29.9K
May 13, 2019
Q3
2018
Sep 30, 2017
$44.9K
Nov 9, 2018
Q2
2018
Jun 30, 2017
$44.9K
Aug 9, 2018
Q1
2018
Mar 31, 2017
$15.0K
May 9, 2018
Q3
2016
Sep 30, 2016
$0
Nov 14, 2016
Q2
2017
Jun 30, 2016
$0
Aug 8, 2017
Q1
2017
Mar 31, 2016
$0
May 15, 2017
Q3
2016
Sep 30, 2015
$59.9K
Nov 14, 2016
Q2
2016
Jun 30, 2015
$77.0K
Aug 15, 2016
Q1
2016
Mar 31, 2015
$57.6K
May 13, 2016
Q3
2015
Sep 30, 2014
$0
Nov 10, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2023
$1.10M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$1.10M
Aug 14, 2024
Q1
2024
Mar 31, 2023
$1.10M
May 9, 2024
Q3
2023
Sep 30, 2022
$1.06M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$1.06M
Aug 9, 2023
Q3
2022
Sep 30, 2021
$33.3K
Nov 2, 2022
Q2
2022
Jun 30, 2021
$33.3K
Aug 11, 2022
Q1
2022
Mar 31, 2021
$33.3K
May 12, 2022
Q3
2021
Sep 30, 2020
$95.8K
Nov 8, 2021
Q3
2020
Sep 30, 2019
$89.8K
Nov 6, 2020
Q2
2020
Jun 30, 2019
$89.8K
Aug 10, 2020
Q3
2019
Sep 30, 2018
$119.8K
Nov 13, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.53M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($5.25M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($1.66M)
May 15, 2025
Q3
2025
Sep 30, 2024
($4.28M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($5.72M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($5.82M)
May 15, 2025
Q3
2024
Sep 30, 2023
($6.06M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($6.06M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($5.51M)
May 9, 2024
Q3
2023
Sep 30, 2022
($5.46M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($5.92M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($5.98M)
May 10, 2023
Q3
2022
Sep 30, 2021
($6.84M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($4.79M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($4.96M)
May 12, 2022
Q3
2021
Sep 30, 2020
($5.45M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($5.61M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($5.05M)
May 10, 2021
Q3
2020
Sep 30, 2019
($4.40M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($3.34M)
Aug 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.58M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($1.84M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($1.95M)
May 15, 2025
Q3
2025
Sep 30, 2024
($4.38M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($5.84M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($5.90M)
May 15, 2025
Q3
2024
Sep 30, 2023
($6.13M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($6.16M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($5.59M)
May 9, 2024
Q3
2023
Sep 30, 2022
($5.46M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($5.93M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($7.72M)
May 10, 2023
Q3
2022
Sep 30, 2021
($6.88M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($4.79M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($6.35M)
May 12, 2022
Q3
2021
Sep 30, 2020
($5.60M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($5.77M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($6.35M)
May 10, 2021
Q3
2020
Sep 30, 2019
($4.56M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($4.52M)
Aug 10, 2020